Jazz Pharmaceuticals (JAZZ) Guidance Looks Conservative After Printing a 43% Conversion Rate - Morgan Stanley
March 2, 2022 6:33 AM
Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $174.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) after revenues ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
